Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

PALACE 4: Apremilast safe, effective in DMARD-naïve psoriatic arthritis

06 May 2018

Use of apremilast monotherapy in the treatment of disease-modifying antirheumatic drugs (DMARDs)-naïve psoriatic arthritis (PsA) patients is well-tolerated and helps improve signs/symptoms over 52 weeks, according to the results of the PALACE 4 trial.

The trial randomized 527 patients with active PsA (mean disease duration, 3.4 years) to treatment with placebo (n=176), apremilast 20 mg twice a day (BID; n=175) or apremilast 30 mg BID (n=176). Those who were assigned to the placebo arm were randomly reassigned to apremilast at week 16 or 24. Apremilast treatment continued to week 52 and extended up to 4 years.

At week 16, the primary endpoint of the proportion of patients achieving 20 percent improvement in ACR response criteria (ACR20) was significantly greater in either apremilast arm than in the placebo arm (28.0 percent with 20 mg vs 15.9 percent; p=0.0062; 30.7 percent with 30 mg vs 15.9 percent; p=0.0010).

Both apremilast doses proved superior to placebo in terms of the mean change in the HAQ Disability Index (HAQ-DI) score at week 16 (−0.17 with 20 mg vs 0.03; p=0.0008; −0.21 with 30 mg vs 0.03; p<0.0001). A similar pattern of results was observed for ACR responses at week 16, swollen/tender joint counts and psoriasis assessments. The observed improvements were sustained through week 52.

Common adverse events (AEs) over 52 weeks included diarrhoea, nausea, headache and upper respiratory tract infection. Most events were mild or moderate in severity. Serious AEs and AEs leading to discontinuation were similar across the three treatment arms. Laboratory abnormalities were infrequent and transient.

In light of the favourable benefit–risk profile of apremilast observed in PALACE 4, researchers pointed out that apremilast represents a potential treatment option for DMARD-naive patients with active PsA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.